Mitsubishi UFJ Asset Management
ABUS icon

Mitsubishi UFJ Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Buy
53,320
+558
+1% +$2.45K ﹤0.01% 993
2026
Q1 		$237K Sell
52,762
-1,304
-2% -$5.7K ﹤0.01% 949
2025
Q4 		$258K Sell
54,066
-19,624
-27% -$88.2K ﹤0.01% 978
2025
Q3 		$335K Buy
73,690
+147
+0.2% +$540 ﹤0.01% 928
2025
Q2 		$227K Sell
73,543
-2,488
-3% -$8.26K ﹤0.01% 964
2025
Q1 		$265K Buy
76,031
+6,371
+9% +$21.2K ﹤0.01% 921
2024
Q4 		$238K Sell
69,660
-12,287
-15% -$45.2K ﹤0.01% 968
2024
Q3 		$315K Sell
81,947
-7,748
-9% -$29.7K ﹤0.01% 912
2024
Q2 		$277K Buy
+89,695
New +$269K ﹤0.01% 925

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mitsubishi UFJ Asset Management's ABUS Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its Arbutus Biopharma (ABUS) stake by 1.1% in Q2 2026, buying an estimated $2.45K and bringing the position to 53,320 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #993.

Mitsubishi UFJ Asset Management first reported a position in ABUS in Q2 2024 and has held it in 9 quarters since. The position peaked at $335K in Q3 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 53,320 shares of Arbutus Biopharma worth $256K as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 558 Arbutus Biopharma shares in Q2 2026, an estimated $2.45K.
  • Arbutus Biopharma made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #993 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Arbutus Biopharma in Q2 2024 and has held it in 9 quarters since.
  • Mitsubishi UFJ Asset Management's Arbutus Biopharma position peaked at $335K in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.